Insights

Here’s why Incannex (ASX:IHL) shares are in a trading halt

The pharmaceutical up-and-comer has requested trading in its shares be placed on hold.
The post Here’s why Incannex (ASX:IHL) shares are in a trading halt appeared first on The Motley Fool Australia. –

The Incannex Healthcare Ltd (ASX: IHL) share price won’t be going anywhere today.  

Shares in the emerging pharmaceutical company were placed in a trading halt before markets opened.

Here’s why.

Incannex shares halted on patent update and ethics approval

Having last traded at 27.5 cents, Incannex requested its shares be placed in a trading halt before the market open.

Incannex cited a material patent update and ethics approval for its research studies. The company did not specify which research trial or which patent was in line to receive ethics clearance.  

Incannex noted that its shares will remain in a trading halt until either the commencement of normal trading on 22nd July 2021 or the earlier release of an announcement.

More on Incannex

Incannex is a clinical-stage pharmaceutical development company that develops medicinal cannabis pharmaceutical products and psychedelic medicine therapies.

The company’s therapies are designed for various medical issues, including anxiety disorders, sleep apnoea, lung inflammation and rheumatoid arthritis.

Incannex has a pipeline of patents including IHL-216A which targets traumatic brain injury and IHL-42X for sleep apnoea.

The Incannex share price has had a stellar 2021, with shares in the company up more than 80% since the start of the year. On a 52-week basis, the Incannex share price has risen nearly 300%.

Apart from today’s announcement, the last piece of price-sensitive news from Incannex was late last week.

The company announced that it engaged Procaps to develop and manufacture its IHL-675A soft gel capsules in preparation for clinical trials.

According to Incannex, its IHL-675A formulation is a multi-use drug that has anti-inflammatory properties. The company also informed investors that it has advanced plans for a phase1 clinical trial to assess IHL-675A soft gel capsules.

Incannex noted that subject to clinical success, the results of the phase 1 clinical trial will form part of 3 US Food and Drug Administration (FDA) applications.

The post Here’s why Incannex (ASX:IHL) shares are in a trading halt appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

PointsBet (ASX:PBH) share price up 3% after announcing plans to enter Arizona
Costa (ASX:CGC) share price edges higher on acquisition update
Ramsay (ASX:RHC) share price rises despite UK acquisition collapse
Afterpay (ASX:APT) share price higher after announcing Money by Afterpay app roll out
Nuix (ASX:NXL) share price plunges 7% in 7 days

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
Trade The US Market With ZERO Brokerage* + FREE Access To Trading Ideas & Value Analysis Tools. Click Here!